Anti-Amyloid Beta Antibody (CNTO 2125) is a recombinant humanized monoclonal antibody targeting human Amyloid Beta (Aβ/Amyloid Beta). Aβ is the core component of amyloid plaques in the Alzheimer's disease (AD) brain, generated from the cleavage of amyloid precursor protein (APP). CNTO 2125 specifically binds to Aβ with high affinity (e.g., EC50 ≈ 9.7 ng/mL), blocking the aggregation of Aβ monomers and promoting the clearance of existing plaques. By targeting the Aβ cascade, this antibody has the potential to protect neurons from Aβ-mediated neurotoxic damage, serving as a critical tool for researching the pathogenesis and immunotherapy of Alzheimer's disease. This antibody features a huIgG1 heavy chain and a hu-kappa light chain.